HC Wainwright Reiterates Buy Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $3.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 203.03% from the company’s current price. Barinthus Biotherapeutics Stock […]
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $3.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 203.03% from the company’s current price. Barinthus Biotherapeutics Stock […]
